{"id":4321,"date":"2018-05-18T09:18:41","date_gmt":"2018-05-18T13:18:41","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=4321"},"modified":"2018-05-18T09:18:41","modified_gmt":"2018-05-18T13:18:41","slug":"kiniksa-pharmaceuticals-ipo-preview-knsa","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/kiniksa-pharmaceuticals-ipo-preview-knsa\/","title":{"rendered":"Kiniksa Pharmaceuticals #IPO Preview ($KNSA)"},"content":{"rendered":"<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/05\/KNSA.jpg\"><img decoding=\"async\" class=\"aligncenter size-full wp-image-4322\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/05\/KNSA.jpg\" alt=\"KNSA\" width=\"201\" height=\"138\" \/><\/a><\/p>\n<p>Company: <strong>Kiniksa Pharmaceuticals, Ltd.<\/strong><br \/>\nSymbol: KNSA<br \/>\nDescription: They are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.<br \/>\nTrade Date: 5\/24<br \/>\nShares: 7 million<br \/>\nPrice Range: $17.00-$19.00<br \/>\nUnderwriter(s): Goldman Sachs, J.P. Morgan<br \/>\nCo-Manager(s): JMP Securities, Wedbush PacGrow<br \/>\nTerms Added: 5-14-18<\/p>\n<p><strong><a href=\"https:\/\/www.sec.gov\/Archives\/edgar\/data\/1730430\/000104746918003731\/a2235626zs-1a.htm\" target=\"_blank\">Link to Prospectus<\/a><\/strong><\/p>\n<p><strong><a href=\"http:\/\/www.retailroadshow.com\/wp\/roadshows.asp\" target=\"_blank\">Link to Retail Roadshow<\/a><\/strong><\/p>\n<p><strong>Business<\/strong>:\u00a0They have a pipeline of product candidates across various stages of development, currently focused on autoinflammatory and autoimmune conditions. They have three clinical-stage product candidates, one of which is anticipated to commence a Phase\u00a03 clinical trial in 2018. They follow a disciplined and methodical approach to selectively identify and acquire product candidates with strong biologic rationales or validated mechanisms of action. They believe that each of their product candidates has the potential to address multiple indications.<\/p>\n<p><a href=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/05\/knsa.drugs_.jpg\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter size-full wp-image-4323\" src=\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/05\/knsa.drugs_.jpg\" alt=\"knsa.drugs\" width=\"672\" height=\"326\" srcset=\"https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/05\/knsa.drugs_.jpg 672w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/05\/knsa.drugs_-600x291.jpg 600w, https:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/05\/knsa.drugs_-300x146.jpg 300w\" sizes=\"(max-width: 672px) 100vw, 672px\" \/><\/a><\/p>\n<p><strong>Insider Buying:\u00a0<\/strong>Certain of their directors and existing shareholders, or their affiliates, have indicated an interest in purchasing up to an aggregate of approximately $50.0\u00a0million of their\u00a0ordinary shares in this offering.<\/p>\n<p><strong>Agreement(s):<\/strong>\u00a0This company has agreements with Regeneron Pharmaceuticals,\u00a0Inc., or Regeneron, MedImmune, Limited, or MedImmune, Biogen MA\u00a0Inc., or Biogen, Novo Nordisk A\/S, or Novo Nordisk.<\/p>\n<p><strong>Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/p>\n<p><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\"><span style=\"font-weight: 400;\">IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n<p><strong>Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0<a href=\"https:\/\/www.ipoboutique.com\/cgi\/ipo-track-record-summary-report.php\"><span style=\"font-weight: 400;\">track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here&#8217;s a<a href=\"http:\/\/www.ipoboutique.com\/blog\/?p=3655\"> 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique&#8217;s service.<\/p>\n<p><b>Indicate with confidence,\u00a0<\/b><a href=\"https:\/\/www.ipoboutique.com\/Subscribe.html\"><b>SUBSCRIBE<\/b><\/a><b>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Company: Kiniksa Pharmaceuticals, Ltd. Symbol: KNSA Description: They are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Trade Date: 5\/24 Shares: 7 million Price Range: $17.00-$19.00 Underwriter(s): Goldman Sachs, J.P. Morgan Co-Manager(s): JMP Securities, Wedbush PacGrow Terms Added: 5-14-18[&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1511],"class_list":["post-4321","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-knsa"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=4321"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4321\/revisions"}],"predecessor-version":[{"id":4324,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/4321\/revisions\/4324"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=4321"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=4321"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=4321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}